Idera Pharmaceuticals Announces Appointment of Mark J. Casey as General Counsel and Secretary of the Board of Directors

Idera Pharmaceuticals, Inc.

, a clinical-stage biopharmaceutical company developing toll-like receptor and RNA therapeutics for patients with cancer and rare diseases, today announced that it has appointed Mark J. Casey as Senior Vice President, General Counsel and Secretary of the Board of Directors. Vincent J. Milano, Chief Executive Officer of Idera Pharmaceuticals stated, "Mark's experience and acumen are perfect matches for Idera and we look forward to the immediate positive impact he will make to our growing team. Importantly, Mark fits incredibly well into the corporate culture we are fostering at Idera that will continue to drive us to delivering therapies for patients suffering from life-threatening diseases whose needs are currently unmet." "I am thrilled to be joining the team at Idera," stated Mark Casey, Idera's General Counsel. "The company's incredible focus on developing targeted therapies for rare diseases and cancers is critically important to patients and I am very passionate about doing my part to contribute to the Idera team's mission." Mr. Casey most recently served as Chief Administrative Officer, Senior Vice President, General Counsel and Secretary of Hologic Incorporated. Prior to Hologic, Mr. Casey, held roles of increasing responsibility at Cytyc Corporation and Boston Scientific Corporation. Mr. Casey received his J.D. from Suffolk University Law School and his Bachelor of Science from Syracuse University.